The company currently markets eight prescription products. The gross proceeds to Aytu from this offering are expected to be $20 million, before deducting the placement agent's fees and other offering expenses payable by Aytu. * aytu bioscience (aytu) - covid-19 igg/igm rapid test is intended for professional use and delivers results between 2 and 10 minutes. 0 Million Registered Direct Offering Priced At-the-Market Wednesday, March 11, 2020 8:00 AM ENGLEWOOD, CO / ACCESSWIRE / March 11, 2020 / Aytu BioScience, Inc. 5 mln Class A units of common stock and warrants at $0. We are one of the sector leaders in Turkey serving superior quality products globally. commercial rights to Tuzistra® XR, the only FDA-approved 12-hour codeine-based antitussive syrup. Friday March 9, 2018 0 comments Tags: Englewood, Aytu BioScience, Josh Disbrow, MiOXSYS. AYTU - key executives, insider trading, ownership, revenue and average growth rates. All amounts are estimates except the Securities and Exchange Commission (the “SEC”) registration fee. In addition, in. This stock closed Monday trading in bullish territory, gaining by 5. As an additional component of Aytu's exclusivity, the company has committed to purchase a minimum of 1,250,000 tests within the first three months of the Agreement. Josh Disbrow, CEO, AYTU, calls refers to the test as "a game-changer". Heading into today, shares of the company. ), a personal health and wellness company focused on women's sexual wellbeing and intimacy. ENGLEWOOD, Colo. " Although the FDA has relaxed rules for COVID-19 tests, it does require manufacturers to validate the tests before use and to notify customers if the tests have not yet been reviewed by the FDA. Aytu BioScience (NASDAQ:AYTU) has filed a preliminary prospectus for a public offering of Class A and Class B Units. Resources for our Markets. On March 19, 2020, Aytu BioScience, Inc. Josh Disbrow, Chief Executive Officer of Aytu BioScience, commented, "Since the Company began taking the fight to COVID-19, we have continued to aggressively search for and evaluate diagnostic tests and other novel technologies that may complement our current product offering and benefit COVID-19 patients. This prospectus supplement No. ENGLEWOOD, CO / ACCESSWIRE / March 19, 2020 / Aytu BioScience, Inc. ("Aytu" or "the. On cue from yesterday's meteoric 489% jump on the news of its exclusive deal for a rapid coronavirus test, Aytu BioScience (NASDAQ:AYTU) has agreed to sell ~7. For financial reporting, their fiscal year ends on June 30th. Detailed company description & address for Aytu BioScience Inc. AYTU expects to pursue U. Stockpence is the best source for smarter, safer, more profitable investing. It is illegal to (or offer to) sell, purchase or trade this offer. 99% of commons at once. 40 premarket - top pct loser among Nasdaq-listed companies ** AYTU offers 19. The gross proceeds to Aytu from this offering are expected to be $20 million, before deducting the placement agent's fees and other offering expenses payable by Aytu. Adding to the downside was this month’s public offering of 18,750,000 shares of its common […]. Void where prohibited by law. ENGLEWOOD -- Aytu BioScience, Inc. The Company currently markets a portfolio of prescription products addressing large primary care and pediatric markets. A number of analysts have recently issued reports on AYTU shares. 455 likes · 75 talking about this · 1 was here. On March 10, 2020, Aytu BioScience, Inc. Aytu BioScience Announces First Commercial Shipment of its 2-10 Minute COVID-19 IgG/IgM Point-of-Care Rapid Test Co-Diagnostics began offering its COVID-19 test to some U. (NASDAQ: AYTU), a specialty life sciences company focused on global commercialization of novel products in the field of urology, today announced it. Each Class A Unit will consist of one share of common stock and one warrant to. The gross proceeds to Aytu from this offering are expected to be approximately $20 million, before deducting the placement agent's fees and other offering expenses payable by Aytu. Real-time exchange rate quote of Aytu Bioscience Inc including detailed information, live chart and news, profile and other market data. This product is for educational purposes only. KenPharm, Aytu and Histogenics battered after discounted share offerings. Again, like many biotech firms that see a big gain following a product announcement, Aytu issued an at-the-market offering of 16 million shares of common stock. Card is limited to one per person, is not transferrable and cannot be reproduced. Securities and Exchange Commission or the Financial Industry Regulatory Authority. 45 per unit, a discount of 18. 03%) Aytu BioScience Announces China Export Clearance of Company's COVID-19 IgG/IgM Rapid Test ACCESSWIRE - Thu Apr 30, 10:45AM CDT. The only place for free North American stock rankings incorporating insider commitment. ENGLEWOOD, CO / ACCESSWIRE / October 5, 2018 / Aytu BioScience, Inc. com, its partners, representatives and employees assume no responsibility or liability for any use or mis-use of the product. Josh Disbrow, CEO, AYTU, calls refers to the test as "a game-changer". Aytu BioScience, Englewood, Colorado. Aytu BioScience Inc. The exercise price on the warrants is $1. Ranked in Safe(er) Stock and These companies keep Americans supplied and offer long-term value to investors. 01 Entry into a Material Definitive Agreement. com use cookies on this site. we add the value to paper. Aytu Bioscience has three amazing drugs in their pipeline and each has billion dollar market potential. 45 - See attachment. Get stock quotes, news, fundamentals and easy to read SEC and SEDI insider filings. Aytu Bioscience Inc (NASDAQ:AYTU) pulled in sales of $3. Securities products and services offered to self-directed investors through ST Invest, LLC. The entire float is unlike 15 million so they got a massive discount. In addition, in the event the warrants are exercised in full, Aytu expects to receive approximately $20 million in additional gross proceeds. BOSTON, April 17, 2020 (GLOBE NEWSWIRE) — Block & Leviton LLP (www. On March 19, 2020, Aytu BioScience, Inc. 15 - Oh crap The "healthcare dedicated institutional investor" turns out to be SABBY MANAGEMENT. 5,514 Pharmaceutical Representative jobs available on Indeed. Buy, Sell or Hold? We'll analyze any stock symbol for free using our market-proven, technical analysis tools. NEW YORK, April 20, 2020 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Aytu BioSciences, Inc. Aytu BioScience's top line mainly comprises product revenues from the sale of Natesto and license revenues. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors (the “Purchasers”), pursuant to which the Company agreed to sell and issue, in a registered direct offering, an aggregate of (i) 16,000,000 shares of the Company’s. (the "Company") entered into Securities Purchase Agreements (the "Purchase Agreement") with two institutional accredited investors (the "Investors") providing for the issuance and sale by the Company (the "Offering") of $10. AYTU now has significant cash. On March 10, 2020, Aytu BioScience (AYTU. 375M equity offering. AYTU Stock Runs Up On Offering News. In addition, in the event the. But it awaits approval from the Food and Drug Administration (FDA) for public use. Aytu Bioscience, Inc. The Complaint alleges violations of the Securities Exchange Act of 1934 against Aytu and its Board of Directors (the "Board") and is captioned Franchi v.   The Company will host a live conference call and. please be advised that your continued use of this site or the products or information provided thereby shall indicate your consent and agreement to these terms and conditions. , a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today announced that it has priced an underwritten public offering of 5,735,000 shares of its common stock and warrants to purchase up to an aggregate of. On March 19, 2020, Aytu BioScience, Inc. 2020-03-11 08:00 ET - News Release. , May 10, 2016 /PRNewswire/ -- Aytu BioScience, Inc. In addition, the Company is also in active discussions with [Aytu BioScience (NASDAQ: AYTU; “Aytu”)], a specialty pharmaceutical company, and marketer of a COVID-19 IgG/IgM Rapid Test, and other large distributors to deploy their respective COVID-19 rapid antibody blood testing solutions. Both Aytu BioScience and Lipocine, Inc. The stock has traded today between $0. Aytu Bioscience, Inc. Access to live, executable, transparent prices. Aytu Announces $20. com, its partners, representatives and employees assume no responsibility or liability for any use or mis-use of the product. As an additional component of Aytu's exclusivity, the company has committed to purchase a minimum of 1,250,000 tests within the first three months of the Agreement. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, today announced that it has entered into a definitive agreement with a single. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today announced new clinical findings that further validate and expand the potential utility of its MiOXSYS System as an advanced tool for assessing oxidative stress in human semen, which is broadly. The specialty pharma company said it has. This was a very big move. Press Release - New York, NY - November 2, 2016 - Nationally recognized securities and corporate law firm Sichenzia Ross Ference Kesner LLP announced today that it has represented Joseph Gunnar & Co. com Aytu used $5 million in cash for operations and exited the quarter with cash balance of ~$2. 0 Million Registered Direct Offering Priced At-the-Market. Aytu BioScience Inc. , a specialty pharmaceutical company, focuses on developing and commercializing novel products in the field of hypogonadism (low testosterone), cough and upper respiratory symptoms, insomnia, and male infertility in the United States and internationally. Aytu has committed to purchase 500,000 tests within one business day from the date of signing of the Agreement. The gross proceeds to Aytu from this offering are expected to be $20 million, before deducting the placement agent's fees and other offering expenses payable by Aytu. Free stock picking trading portfolio and contest for all. In addition, in the event. Distributed by Public, unedited and unaltered, on 31 October 2019 22:11:02 UTC. 16% since the beginning of the year. In addition, in the event the warrants are exercised in full, Aytu expects to receive approximately $20 million in additional gross proceeds. The notice included securities offered of Equity,Option, Warrant or Other Right to Acquire Another Security,Other. (NASDAQ:AYTU) (the “Company”), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, is pleased to report the results of the Company’s 2020 Annual Meeting. (AYTU) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. , a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today announced that it has priced an underwritten public offering of 5,735,000 shares of its common stock and warrants to purchase up to an aggregate of. Our commitment to improving peoples' health is unwavering. The company markets Natesto, a nasal gel for the treatment of. Heading into today, shares of the company. 15%, but now up 30% in After Hours trading. The company announced the sales volume surrounding Natesto. aytu bioscience inc (aytu): * aytu bioscience (aytu) - received confirmation from u. Both Aytu BioScience and Lipocine, Inc. The gross proceeds to Aytu from this offering are expected to be approximately $20 million, before deducting the placement agent's fees and other offering expenses payable by Aytu. Benzinga Newdesk, Benzinga Staff Writer {{following ? "Following" : "Follow"}}. You just read: Aytu BioScience Announces Pricing of $12,000,000 Public Offering. In the release, the company said that it will sell 16 million shares of common stock and warrants to purchase an additional 16 million shares at a combined purchase price of $1. KenPharm, Aytu and Histogenics battered after discounted share offerings. 0 million, before deducting the placement agent's fees and other estimated offering expenses payable by Aytu. The gross proceeds to Aytu from this offering are expected to be approximately $9. In addition, prior to the Effective Time, Aytu intends to make an offer (the "Warrant Offer") to certain holders of Target's warrants, including those that contain a right to receive a cash payment in connection with the Merger (the "Cash Out Right"). 18: Aytu BioScience Provides Fiscal Second Quarter 2018 Business Update - Live Conference Call and Webcast Today at 4:30 pm ET: PR Newswire: 01. In addition, in the event. Aytu BioScience, Inc. Unlike other intelligence solutions, BCIQ exclusively supports the unique needs of the biopharma industry and. 66 million for the 12 months period that ended on June 30, 2018 to $7. com use cookies on this site. DISCLAIMER: Aytu BioScience has notified the FDA that we have validated and will begin offering the COVID-19 IgG/IgM Rapid Test. Access to live, executable, transparent prices. 53 , and has now gained 3 days in a row. Get stock quotes, news, fundamentals and easy to read SEC and SEDI insider filings. 16 and has grown by 30% today. For the biopharma industry investment, business development and competitive intelligence professionals who require information to support financing, partnering and licensing activities, BCIQ provides accurate information and context to support profitable and strategic decision making. healthcare supply chain. You may enter multiple symbols, separated by spaces or commas, up to a maximum of 100 characters. , May 11, 2017 ENGLEWOOD, Colo. Is For example Discover is offering this insane. See Aytu BioScience price target based on 2 analysts offering 12 month price targets for Aytu BioScience in the last 3 months. Unlike other intelligence solutions, BCIQ exclusively supports the unique needs of the biopharma industry and. Fast funding for your business. Apply now Applying will not affect your credit score1 Business Loans from – Rates as low as %2 Approvals as fast as Funding solutions tailored to your business needs Line of Credit Quick access to revolving line Credit lines up to $250,000 Only pay for what you use No …. About Aytu BioScience, Inc. The Company intends to use the net proceeds from this offering for working capital, general corporat. The company currently markets Natesto®, the only FDA-approved nasal formulation of testosterone for men with hypogonadism (low testosterone, or "Low T"). The next day, Aytu announced an at-the-market offering of 16 million shares of common stock plus an associated warrant priced at $1. 75 per share, outstanding warrants to purchase (i) 1,733,322 shares of Common Stock with an exercise price of $6. AYTU Long Stock. 0 million of, (i) shares of the Company’s Series F Convertible (the “Preferred Stock”) which are. Resources for our Markets. Trader Updates. This prospectus supplement No. 5 mln Class A units of common stock and warrants at $0. 99 per share and is currently. As an additional component of Aytu's exclusivity, the company has committed to purchase a minimum of 1,250,000 tests within the first three months of the Agreement. (AYTU) is a "Buy". The gross proceeds to Aytu from this offering are expected to be approximately $20 million, before deducting the placement agent's fees and other offering expenses payable by Aytu. Aytu BioScience Inc AYTU Vitals. This accounts for preferreds in recent offering. The Company intends to use the net proceeds from this offering for working capital, general corporate purposes, and to continue the commercialization of. Aytu BioScience Announces Pricing of $7. 12:45 PM ET. This makes me conclude Aytu made $700,000 profit on the 100,000 tests sold already and future profit of $3. Traders and investors may also choose to study the ATR or Average True Range when concentrating on technical inventory assessment. 0 Million Registered Direct Offering Priced At-the-Market ACCESSWIRE Mar-10-20 08:05AM Aytu BioScience Secures Exclusive U. ("Aytu" or "the. Aytu Announces $20 Million Registered Direct Offering Priced At-the-Market Thursday, March 12, 2020 8:00 AM ENGLEWOOD, CO / ACCESSWIRE / March 12, 2020 / Aytu BioScience, Inc. The specific nature of the offering has yet to be determined. On March 19, 2020, Aytu BioScience, Inc. gov - 7 - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(A) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate. Free seasonal charts on hot stocks to buy today. has transformed tiny Aytu Bioscience (AYTU) into an overnight Covid-19 success story, with a soaring share price to. Whalewisdom has at least 55 Form 4 filings The firm last filed a Form D notice of exempt offering of securities on 2019-10-31. The offering priced at $1. (AYTU) closed at $1. Where is the trend headed and how much momentum is driving it? Our free report will give you the stock trend outlook. Shares of penny stock Aytu Bioscience Inc (NASDAQ: AYTU) were ripping higher Tuesday after the company said it signed a deal to distribute a COVID-19 test. Press Release - New York, NY - November 2, 2016 - Nationally recognized securities and corporate law firm Sichenzia Ross Ference Kesner LLP announced today that it has represented Joseph Gunnar & Co. 375M equity offering. The company currently markets eight prescription products. ADMA closed Monday's trading at $3. About Aytu BioScience, Inc. Aytu BioScience Announces First Commercial Shipment of its 2-10 Minute COVID-19 IgG/IgM Point-of-Care Rapid Test Co-Diagnostics began offering its COVID-19 test to some U. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual investors, professional money managers, active traders, and corporate executives informed on what's moving stocks. 67% plummeted 33% and of KemPharm Inc. 99% of commons at once. 5,514 Pharmaceutical Representative jobs available on Indeed. of the FDA’s Policy for Diagnostic Tests for Coronavirus Disease-2019 during the Public Health Emergency. is acting as the exclusive placement agent for the offering. In short, AYTU expects to do many things, and promises to do nothing. Get stock quotes, news, fundamentals and easy to read SEC and SEDI insider filings. Van Meerten Stock Picks. In addition, in the event the warrants are exercised in full, Aytu expects to receive approximately $20 million in additional gross proceeds. Aytu Bioscience Inc (NASDAQ:AYTU) pulled in sales of $3. The gross proceeds to Aytu from this offering are expected to be approximately $9. The test is intended for professional use and delivers results between 2 and 10 minutes at the point-of-care. Crazy moves in AYTU today. 2 million which includes the full exercise of the underwriters. the completion of the registered direct offering. Heading into today, shares of the company. The test is being made available under compliance with Section IV. 2M, Up 77% Year- over-Year and 121% Sequentially: ACCESSWIRE: 06. 51% increase from the last price of $1. We offer daily stock market & cryptocurrency updates and investing advice. Its products include Natesto, Tuzistram, ZolpiMist and. Free seasonal charts on hot stocks to buy today. 84% off its 52 week high of $2. (AYTU) has shown a return of 51. 00 per share, which were originally issued to investors in the. Both Aytu BioScience and Lipocine, Inc. , a specialty healthcare company, focuses on developing and commercializing novel products in the field of hypogonadism (low testosterone), insomnia, and male infertility in the United States and internationally. Find the latest Eps Diluted (Quarterly) for Aytu Bioscience, Inc. Its ONE institutional healthcare investor who made the purchase. 55 in the latest trading session, marking a -1. com), a national securities litigation firm, is investigating Aytu BioScience, Inc. Aytu expects delivery of its first shipment of 100,000 tests this week. After Ampio Biopharmaceuticals Inc (NYSEMKT:AMPE) distributed most of its 11,626,068 shares of Aytu to Ampio’s current shareholders, AYTU has been under pressure as these shares have been dumped onto the market. Aytu BioScience, Inc. ENGLEWOOD, Colo. Distributed by Public, unedited and unaltered, on 31 October 2019 22:11:02 UTC. AYTU - Aytu BioScience Inc. 5 Million Public Offering of Common Stock and Warrants Englewood, CO - May 2, 2016 - Aytu BioScience, Inc. , a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today announced that it has priced an underwritten public offering of 5,735,000 shares of its common stock and warrants to purchase up to an aggregate of. (NASDAQ:AYTU) (the “Company”), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced today that the Company will present its operational results for the quarter ended March 31, 2020 on May 14, 2020, at 4:30 p. Aytu BioScience is a commercial-stage specialty pharmaceutical company focused on commercializing novel products that address significant patient needs. Aytu Announces $20 Million Registered Direct Offering Priced At-the-Market ACCESSWIRE Aytu BioScience, Inc. Aytu BioScience is a commercial-stage specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs. On October 11, 2019, Aytu BioScience, Inc. Aytu BioScience Inc. ("Aytu" or "the. This stock closed Monday trading in bullish territory, gaining by 5. 7 million shares at $1. The following table sets forth the costs and expenses payable in connection with the offering of the securities being registered, all of which will be paid by Aytu BioScience, Inc. 40 premarket - top pct loser among Nasdaq-listed companies ** AYTU offers 19. ENGLEWOOD, CO / ACCESSWIRE / March 12, 2020 / Aytu BioScience, Inc. The gross proceeds to Aytu from this offering are expected to be $20 million, before deducting the placement agent's fees and other offering expenses payable by Aytu. , May 11, 2017 ENGLEWOOD, Colo. As mentioned above, Aytu Bioscience offered investors a key update this morning. Shares of penny stock Aytu Bioscience Inc (NASDAQ: AYTU) were ripping higher Tuesday after the company said it signed a deal to distribute a COVID-19 test. Aytu recently acquired exclusive U. "It’s a very simple test that can be performed at the point of care, so in a doctor’s office. com, its partners, representatives and employees assume no responsibility or liability for any use or mis-use of the product. In addition, in. Aytu BioScience Inc is a specialty pharmaceutical company commercializing novel products addressing patient needs. In addition, the Company is also in active discussions with [Aytu BioScience (NASDAQ: AYTU; “Aytu”)], a specialty pharmaceutical company, and marketer of a COVID-19 IgG/IgM Rapid Test, and other large distributors to deploy their respective COVID-19 rapid antibody blood testing solutions. Aytu has committed to purchase 500,000 tests within one business day from the date of signing of the Agreement. ENGLEWOOD, CO / ACCESSWIRE / March 19, 2020 / Aytu BioScience, Inc. Is Too Expensive. ENGLEWOOD, Colo. VIDEO FINANCIAL REPORTING Why invest in is the first financial video platform where you can easily search through thousands of videos describing global secur. 5 MILLION SHARES OF COMMON STOCK. Aytu BioScience, Inc. In February 2020, the Company raised net proceeds of approximately $88. Last week, Aytu BioScience announced that it licensed United States rights to commercialize a rapid COVID-19 diagnostic test from a Chinese company. if you do not agree with any term or provision of our terms and conditions, please exit the site immediately. 0 Million Registered Direct Offering Priced At-the-Market ACCESSWIRE Mar-10-20 08:05AM Aytu BioScience Secures Exclusive U. Aytu Announces $20 Million Registered Direct Offering Priced At-the-Market Thursday, March 12, 2020 8:00 AM ENGLEWOOD, CO / ACCESSWIRE / March 12, 2020 / Aytu BioScience, Inc. In addition, in the event the warrants are exercised in full, Aytu expects to receive approximately $20 million in additional gross proceeds. , May 11, 2017. Aytu Announces $20. Aytu BioScience is a commercial-stage specialty pharmaceutical company focused on commercializing novel products that address significant patient needs. News Headlines for Aytu BioScience Inc. 00 per share, which were originally issued to investors in the. , Company's Series F convertible preferred stock and the exercisability of PIPE warrants issued in a private placement offering that closed October 16, 2019; and (2) the. 0 analysts have. super_trades Mar 19, 5:52 AM. We are one of the sector leaders in Turkey serving superior quality products globally. Aytu Announces $20 Million Registered Direct Offering Priced At-the-Market; Aytu BioScience Expands Its Distribution Rights for Coronavirus 2019 (COVID-19) Point-of-Care Rapid Test to Canada and Mexico. ET PR Newswire ENGLEWOOD, Colo. healthcare supply chain. This has largely been driven by mergers and acquisitions, as well as positive results from drug tests. ” Today, many retail investors are Googling “corona virus” – so AYTU’s news is timely. Akers Biosciences Inc (AKER) currently trades at $6. Aytu Bioscience Inc (NASDAQ:AYTU) shares gapped down before the market opened on Wednesday. 0 Million Registered Direct Offering Priced At-the-Market Wednesday, March 11, 2020 8:00 AM ENGLEWOOD, CO / ACCESSWIRE / March 11, 2020 / Aytu BioScience, Inc. Natesto, Zolpimist, and Tuzistra each offer best-in-class potential and combine to target a. Securities products and services offered to self-directed investors through ST Invest, LLC. The next day, Aytu announced an at-the-market offering of 16 million shares of common stock plus an associated warrant priced at $1. 455 likes · 75 talking about this · 1 was here. Josh Disbrow, CEO, AYTU, calls refers to the test as "a game-changer". Bilibili Inc. AYTU Stock Runs Up On Offering News. 12:45 PM ET. Aytu BioScience Expands Its Distribution Rights for Coronavirus 2019 (COVID-19) Point-of-Care Rapid Test to Canada and Mexico oggi dovrebbe 19-03-20, 14:45 #407. Meanwhile, the Dow lost 1. See Aytu BioScience price target based on 2 analysts offering 12 month price targets for Aytu BioScience in the last 3 months. “It’s a 2 to 10 minute result," Josh Disbrow, CEO of Aytu BioScience, said. Aytu BioScience is a commercial-stage specialty pharmaceutical company focused on commercializing novel products that address significant patient needs. In addition, in the event the warrants are exercised in full, Aytu expects to receive approximately $20 million in additional gross proceeds. 8M common shares to an unnamed. Aytu BioScience, Inc. Friday March 9, 2018 0 comments Tags: Englewood, Aytu BioScience, Josh Disbrow, MiOXSYS. 99 per share and is currently. Aytu BioScience Inc is a specialty pharmaceutical company commercializing novel products addressing patient needs. Enter any symbol for a free, instant analysis. Aytu BioScience, Inc. ("Aytu") (OTCQX: AYTU), a specialty pharmaceutical company focused on commercializing novel products in the field of urology, today announced that it has priced an underwritten. , a specialty pharmaceutical company, focuses on developing and commercializing novel products in the field of hypogonadism (low testosterone), cough and upper respiratory symptoms, insomnia, and male infertility in the United States and internationally. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an institutional investor (the “Purchaser”), pursuant to which the Company agreed to sell and issue, in a registered direct offering, an aggregate of (i) 4,450,000 shares of the Company’s common. The Company intends to use the net proceeds from this offering for working capital, general corporate purposes, and to continue the commercialization of. Detailed company description & address for Aytu BioScience Inc. Aytu Bioscience Inc (AYTU) Outpaces Stock Market Gains: What You Should Know Posted By: Editor [unable to retrieve full-text content]In the latest trading session, Aytu Bioscience Inc (AYTU) closed at $1. 15 - Oh crap The "healthcare dedicated institutional investor" turns out to be SABBY MANAGEMENT. An Experimental Ultraviolet Light Treatment for Covid-19 Takes Political Heat The Wall Street Journal Interactive Edition. 01 Entry into a Material Definitive Agreement. published this content on 31 October 2019 and is solely responsible for the information contained therein. regulatory clearance and expects to consult with the FDA about qualifying the test under FDA's Emergency Use Authorization. But it awaits approval from the Food and Drug Administration (FDA) for public use. The CE-marked tests just require a drop of blood from a finger prick and the results are known on the spot (i. , a specialty pharmaceutical company, focuses on developing and commercializing novel products in the field of hypogonadism (low testosterone), cough and upper respiratory symptoms, insomnia, and male infertility in the United States and internationally. Aytu Bioscience shares last traded at $1. AYTU BIOSCIENCE, INC. Aytu BioScience, Inc. Shares of biotech companies Aytu BioScience Inc. 12:45 PM ET. 0 million, before deducting the placement agent's fees and other estimated offering expenses payable by Aytu. Aytu Announces $9. (the "Company") entered into Securities Purchase Agreements (the "Purchase Agreement") with two institutional accredited investors (the "Investors") providing for the issuance and sale by the Company (the "Offering") of $10. Nachrichten » Aytu BioScience, Inc. In addition, in the event the warrants are exercised in full, Aytu expects to receive approximately $20 million in additional gross proceeds. Distribution Agreement for Coronavirus 2019 (COVID-19) Point-of-Care Rapid Test ACCESSWIRE +489. Aytu BioScience, Inc. Prospectus Supplement No. AYTU Stock Rockets On Diagnostic News. The Company expects to receive an initial product shipment in three to four weeks, pending the timing of required regulatory, customs, and importation activities. Wainwright & Co. 9 Aytu BioScience reviews. ADMA closed Monday's trading at $3. : Aytu BioScience Announces Closing of $15. Aytu BioScience is a commercial-stage specialty pharmaceutical company focused on commercializing novel products that address significant patient needs. Aytu Announces $9. 10:02 AM ET. ENGLEWOOD, Colo. AYTU will be responsible for obtaining, at its expense, all Governmental Approvals and permits necessary for AYTU's use of any Product Manufactured hereunder. 27, 2016 /PRNewswire/ — Aytu BioScience, Inc. The average price target is $3. Free seasonal charts on hot stocks to buy today. 25 per unit. Aytu and Innovus Shareholder Meetings to Approve Merger Scheduled for February 13, 2020 ENGLEWOOD, CO & SAN DIEGO, CA / ACCESSWIRE / January 27, 2020 / Aytu BioScience, Inc. 67% plummeted 33% and of KemPharm Inc. Read More Its products include Natesto, Tuzistram, ZolpiMist and MiOXSYS. Try our All In One Message Board search. AYTU BIOSCIENCE, INC. Ended the day down 34. Member FINRA / SIPC. As always, use your best judgment when investing. AYTU - key executives, insider trading, ownership, revenue and average growth rates. 20: Aytu BioScience to Report Fiscal Q2 FY 2020 Results and Business Update: ACCESSWIRE: 05. The Company intends to use the net proceeds from this offering for working capital, general corporate purposes, and to continue the commercialization of. Aytu Announces $20 Million Registered Direct Offering Priced At-the-Market Thursday, March 12, 2020 8:00 AM ENGLEWOOD, CO / ACCESSWIRE / March 12, 2020 / Aytu BioScience, Inc. On March 19, 2020, Aytu BioScience, Inc. 23% move from the prior day. Aytu Bioscience Inc (OTCMKTS:AYTU) has been a disappointment so far this year. 0 Million Registered Direct Offering Priced At-the-Market Aytu BioScience Secures Exclusive U. The Zestra woman is sophisticated. 0 million, before deducting the placement agent's fees and other estimated offering expenses payable by Aytu. Aytu BioScience, Inc. Aytu BioScience reserves the right to rescind, revoke, or amend this offer without notice. On cue from yesterday's meteoric 489% jump on the news of its exclusive deal for a rapid coronavirus test, Aytu BioScience (NASDAQ:AYTU) has agreed to sell ~7. 2M, Up 77% Year- over-Year and 121% Sequentially: ACCESSWIRE: 06. Heading into today, shares of the company. (the "Company") entered into a securities purchase agreement (the "Purchase Agreement") with certain institutional investors (the "Purchasers"), pursuant to which the Company agreed to sell and issue, in a registered direct offering, an aggregate of (i) 12,539,197 shares of the Company. Shares of biotech companies Aytu BioScience Inc. published this content on 31 October 2019 and is solely responsible for the information contained therein. - AYTU: 2020-04-30 11:46: U:AYTU: News Release: Aytu BioScience Announces China Export Clearance of Company's COVID-19 IgG/IgM Rapid Test: 2020-04-27 09:56: U:AYTU: News Release. Garden Grove doctor one of first in U. ENGLEWOOD, Colo. Almost as bad as Susquehannah. commercial rights to Tuzistra® XR, the only FDA-approved 12-hour codeine-based antitussive syrup. The gross proceeds to Aytu from this offering are expected to be approximately $9. AYTU investment & stock information. Aytu Bioscience shares last traded at $1. Aytu Announces $20M Registered Direct Offering Priced At-The-Market. ("Aytu") (OTCQX: AYTU), a specialty pharmaceutical company focused on commercializing novel products in the field of urology, today announced that it has priced an underwritten public offering of 18,750,000 shares of its common stock and warrants to purchase up to an aggregate of 18,750,000 shares of its common stock at a. Shares of Aytu BioScience Inc. Zacks Investment Research raised […]. Aytu Bioscience (NASDAQ:AYTU) files a prospectus for a $12. In addition, in. Aytu BioScience, Inc. Our commitment to improving peoples' health is unwavering. Any user of NetDania software must be an existing client of one of our supported brokers. The net proceeds from the offering will be used for working capital, general corporate purposes, and continued commercialization of the company’s products. Each warrant will be exercisable for a period commencing on the date of. Aytu BioScience Inc is a specialty pharmaceutical company commercializing novel products addressing patient needs. The company currently markets a portfolio of. Each Class A Unit will consist of one share of common stock and one warrant to. On March 19, 2020, Aytu BioScience, Inc. 45 per unit, a discount of 18. The company currently markets Natesto®, the only FDA-approved nasal formulation of testosterone for men with hypogonadism (low testosterone, or "Low T"). 5M against $15. 5,514 Pharmaceutical Representative jobs available on Indeed. NYSE Bonds. , May 2, 2016 /PRNewswire/ -- Aytu BioScience, Inc. 25 per share and warrant. In addition, in. Aytu Bioscience serves customers worldwide. Whalewisdom has at least 55 Form 4 filings The firm last filed a Form D notice of exempt offering of securities on 2019-10-31. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an institutional investor (the “Purchaser”), pursuant to which the Company agreed to sell and issue, in a registered direct offering, an aggregate of (i) 4,450,000 shares of the Company’s common. Aytu Bioscience Inc (NASDAQ:AYTU) shares gapped down before the market opened on Wednesday. Aytu Bioscience shares last traded at $1. Following the closing of this offering, the Company's pro forma cash balance as of September 30, 2019 would have been approximately $17. Aytu BioScience Announces Pricing of $7. (AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs. The gross proceeds to Aytu from this offering are expected to be approximately $20 million, before deducting the placement agent's fees and other offering expenses payable by Aytu. This product is for educational purposes only. (NASDAQ:AYTU), (the "Company"), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs announced today that it began shipping its Coronavirus Disease 2019 ("COVID-2019") IgG/IgM Rapid Test to U. The gross proceeds to Aytu from this offering are expected to be $20 million, before deducting the placement agent's fees and other offering expenses payable by Aytu. 01 Entry into a Material Definitive Agreement. Aytu Bioscience, Inc. In the release, AYTU said that it expects for the offering to close around March 13, 2020. (NASDAQ:AYTU), a. Our commitment to improving peoples' health is unwavering. 9) NATESTO is seeing exponential growth in US 10) AYTU Insiders have bought significant amount of shares at. The CE-marked tests just require a drop of blood from a finger prick and the results are known on the spot (i. None of the information presented should be construed as an offer to sell or buy any particular security. The exercise price on the warrants. On March 10, Aytu Bioscience (AYTU) spiked up from $0. In the release, AYTU said that it expects for the offering to close around March 13, 2020. Aytu BioScience, Inc. Anyway, ZOG is a huge diagnostics company, with over $1 billion market cap. Just cause companies have similar products or even the same products doesnt mean their share prices will be the same. 0 million, before deducting the placement agent's fees and other estimated offering expenses payable by Aytu. 52, with a volume of 14,191,778 shares trading hands. ( AYTU ) has received the go-ahead from the FDA to commence distribution of its Coronavirus Disease 2019 IgG/IgM Rapid Test throughout the United States. please be advised that your continued use of this site or the products or information provided thereby shall indicate your consent and agreement to these terms and conditions. The entire float is unlike 15 million so they got a massive discount. Aytu recently acquired exclusive U. , a specialty healthcare company, focuses on developing and commercializing novel products in the field of hypogonadism (low testosterone), insomnia, and male infertility in the United States and internationally. Aytu Announces $9. Apply to Pharmaceutical Sales Representative and more!. , Company's Series F convertible preferred stock and the exercisability of PIPE warrants issued in a private placement offering that closed October 16, 2019; and (2) the. BRIEF-Aytu Bioscience Announces Pricing Of $12 Mln Public Offering * AYTU BIOSCIENCE ANNOUNCES PRICING OF $12,000,000 PUBLIC OFFERING BRIEF-Aytu BioScience Provides Update On The Continued Growth. Apply to Pharmaceutical Sales Representative, Customer Service Representative, Sales Representative Entry Level and more!. The company announced the sales volume surrounding Natesto. 33 million shares, representing 52% of the shares outstanding, that priced at $3. The gross proceeds to Aytu from this offering are expected to be approximately $9. , May 11, 2017. taking Partial only because I had bad entry and got caught in offering that was not expected 3k left in alert. Real-time trade and investing ideas on Aytu Bioscience Inc AYTU from the largest community of traders and investors. In addition, in the event the warrants are exercised in full, Aytu expects to receive approximately $20 million in additional gross proceeds. 2 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option. (AYTU) has shown a return of 51. AYTU / Aytu BioScience, Inc. You may enter multiple symbols, separated by spaces or commas, up to a maximum of 100 characters. This makes me conclude Aytu made $700,000 profit on the 100,000 tests sold already and future profit of $3. As it was talked about by some getting Biolidics was a key move, and reduced the supply chain risk. by Jacob Saphir. Aytu's strategy is to continue building its. Adding to the downside was this month’s public offering of 18,750,000 shares of its common […]. AYTU expects to pursue U. About Aytu BioScience, Inc. (AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs. In addition, in. Following the closing of this offering, the Company's pro forma cash balance as of September 30, 2019 would have been approximately $17. Aytu BioScience is a commercial-stage specialty pharmaceutical company focused on commercializing novel products that address significant patient needs. The primary care portfolio. ENGLEWOOD, Colo. We offer daily stock market & cryptocurrency updates and investing advice. ENGLEWOOD, CO / ACCESSWIRE / May 7, 2020 / Aytu BioScience, Inc. Both Aytu BioScience and Lipocine, Inc. AYTU | Complete Aytu BioScience Inc. She wants to make waves in everything. ET PR Newswire ENGLEWOOD, Colo. Aligned with AYTU's other novel products, Tuzistra® XR significantly differentiates itself from similar suppressants in its field by being the only codeine-based antitussive product to offer a 12-hour delivery duration, relative to the short-acting 4 to 6-hour dosing duration of other available treatments. reported that its Total Revenue rose from $3. The Company currently markets a portfolio of prescription products addressing large primary care and pediatric markets. Aytu BioScience announced that it signed an exclusive distribution agreement for the right to commercialize a clinically validated and commercially used coronavirus 2019, or COVID-19, IgG/IgM rapid test. com use cookies on this site. The company currently markets eight prescription products. as Lead Manager in a firm commitment underwritten public offering of equity securities of Aytu. All amounts are estimates except the Securities and Exchange Commission (the "SEC") registration fee. 52, with a volume of 14,191,778 shares trading hands. In addition, the company is battling some balance sheet hurdles, with cash levels struggling to keep up with current liabilities ($5. NetDania is a pure technology provider offering its software with broker integration. The gross proceeds to Aytu from this offering are expected to be approximately $9. 56%) over yesterday's $0. Ranked in Safe(er) Stock and These companies keep Americans supplied and offer long-term value to investors. 2 analysts offering the recommendations for the stock have a consensus rating of 1. The primary care portfolio. Find recent news headlines for a specific symbol on this page. No hedge fund would purchase a HIGHER stake in a competitive position unless they firmly believe that their product is better. (AYTU) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. ENGLEWOOD -- Aytu BioScience, Inc. ENGLEWOOD, CO / ACCESSWIRE / October 5, 2018 / Aytu BioScience, Inc. , a specialty healthcare company, focuses on developing and commercializing novel products in the field of hypogonadism (low testosterone), insomnia, and male infertility in the United States and internationally. 66 million for the 12 months period that ended on June 30, 2018 to $7. Ended the day down 34. ("Aytu") (OTCQX: AYTU), a specialty pharmaceutical company focused on commercializing novel products in the field of urology, today announced that it has priced an underwritten. The gross proceeds to Aytu from this offering are expected to be approximately $20 million, before deducting the placement agent's fees and other offering expenses payable by Aytu. Get the latest Aytu Bioscience, Inc. is a specialty pharmaceutical company, which focuses on identifying, acquiring, and commercializing novel products. taking Partial only because I had bad entry and got caught in offering that was not expected 3k left in alert. Aytu BioScience (NASDAQ:AYTU) has filed a preliminary prospectus for a public offering of Class A and Class B Units. ENGLEWOOD, CO / ACCESSWIRE / April 3, 2020 / Aytu BioScience, Inc. Barron's also provides information on historical stock ratings, target prices, company earnings, market valuation and more. AYTU had potential in its stock price before doing 20 offerings in one month diluting shareholders. (NASDAQ:AYTU). AYTU - key executives, insider trading, ownership, revenue and average growth rates. Aytu BioScience Inc. 27, 2016 /PRNewswire/ — Aytu BioScience, Inc. We are one of the sector leaders in Turkey serving superior quality products globally. The information on this Website is not reliable and not intended to provide tax, legal, or investment advice. 5 million in a public offering. 11) The reason for including preferreds in offering is so certain institutions wont have more than 4. 01 Entry into a Material Definitive Agreement. The gross proceeds to Aytu from this offering are expected to be approximately $9. In the release, AYTU said that it expects for the offering to close around March 13, 2020. Anyway, ZOG is a huge diagnostics company, with over $1 billion market cap. The next day, Aytu announced an at-the-market offering of 16 million shares of common stock plus an associated warrant priced at $1. In addition, in the event the warrants are exercised in full, Aytu expects to receive approximately $20 million in additional gross proceeds. super_trades Mar 19, 5:52 AM. Aytu Bioscience, Inc. Get stock quotes, news, fundamentals and easy to read SEC and SEDI insider filings. ENGLEWOOD, CO / ACCESSWIRE / March 19, 2020 / Aytu BioScience, Inc. BRIEF-Aytu Bioscience Announces Pricing Of $12 Mln Public Offering * AYTU BIOSCIENCE ANNOUNCES PRICING OF $12,000,000 PUBLIC OFFERING. 740 Pharmaceutical Sales Representative jobs available on Indeed. See Aytu BioScience price target based on 2 analysts offering 12 month price targets for Aytu BioScience in the last 3 months. ENGLEWOOD, CO / ACCESSWIRE / May 7, 2020 / Aytu BioScience, Inc. Aytu BioScience's top line mainly comprises product revenues from the sale of Natesto and license revenues. Histogenics, Aytu BioScience and KenPharm shares tumble on share offerings. Aytu Announces $20M Registered Direct Offering Priced At-The-Market. 0 Million Registered Direct Offering Priced At-the-Market Aytu BioScience Secures Exclusive U. 5 million in a public offering. No hedge fund would purchase a HIGHER stake in a competitive position unless they firmly believe that their product is better. AYTU shares opened nearly 275% higher today at $1. 07 until finishing in the latest session at $1. 348 closing price. Performance wise, AYTU stock has recently shown investors 8. We offer daily stock market & cryptocurrency updates and investing advice. Unlike other intelligence solutions, BCIQ exclusively supports the unique needs of the biopharma industry and. 51% increase from the last price of $1. Offer good only in the USA and void where prohibited by law, taxed, or restricted. Aytu BioScience announced that it signed an exclusive distribution agreement for the right to commercialize a clinically validated and commercially used coronavirus 2019, or COVID-19, IgG/IgM rapid test. As an additional component of Aytu's exclusivity, the company has committed to purchase a minimum of 1,250,000 tests within the first three months of the Agreement. This stock closed Monday trading in bullish territory, gaining by 5. (NASDAQ:AYTU) (the “Company”), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced today that the Company will present its operational results for the quarter ended March 31, 2020 on May 14, 2020, at 4:30 p. The other point is that Sabby has a much higher stake in Aytu than CODX. ENGLEWOOD, CO / ACCESSWIRE / October 5, 2018 / Aytu BioScience, Inc. " Although the FDA has relaxed rules for COVID-19 tests, it does require manufacturers to validate the tests before use and to notify customers if the tests have not yet been reviewed by the FDA. ENGLEWOOD, Colo. Shares of biotech companies Aytu BioScience Inc. The following table sets forth the costs and expenses payable in connection with the offering of the securities being registered, all of which will be paid by Aytu BioScience, Inc. Adding to the downside was this month's public offering of 18,750,000 shares of its common […]. The exercise price on the warrants. To Prospectus Dated January 15, 2020. ), a personal health and wellness company focused on women's sexual wellbeing and intimacy. This prospectus supplement No. (AYTU) has shown a return of 51. Detailed company description & address for Aytu BioScience Inc. 2M, Up 77% Year- over-Year and 121% Sequentially: ACCESSWIRE: 06. Sorry but AYTU will never hit $15 or $25. 12:45 PM ET. 9 Aytu BioScience reviews. Member FINRA / SIPC. 27, 2016 /PRNewswire/ — Aytu BioScience, Inc. But when they take a long position, the stock generally does really well. 66 million for the 12 months period that ended on June 30, 2018 to $7. AYTU Long Stock. Aytu BioScience Announces Pricing of $7. to offer coronavirus rapid blood test Test used in Asia can provide results in 10 minutes with simple fingerstick; DA says doctor made 'no false claims'. 08% PDF Aytu Bioscience gained 4. Both Aytu BioScience and Lipocine, Inc. , May 11, 2017. Get stock quotes, news, fundamentals and easy to read SEC and SEDI insider filings. AYTU / Aytu BioScience, Inc. For financial reporting, their fiscal year ends on June 30th. On March 10, 2020, Aytu BioScience, Inc. 0 Million Registered Direct Offering Priced At-the-Market Wednesday, March 11, 2020 8:00 AM ENGLEWOOD, CO / ACCESSWIRE / March 11, 2020 / Aytu BioScience, Inc. As it was talked about by some getting Biolidics was a key move, and reduced the supply chain risk. Aytu BioScience Provides Third Quarter Fiscal 2017 Business Update Live Conference Call and Webcast TODAY at 4:30 p. is a specialty pharmaceutical company, which focuses on identifying, acquiring, and commercializing novel products. Common Stock (AYTU) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Is Too Expensive. Aytu BioScience announced that it signed an exclusive distribution agreement for the right to commercialize a clinically validated and commercially used coronavirus 2019, or COVID-19, IgG/IgM rapid test. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors (the “Purchasers”), pursuant to which the Company agreed to sell and issue, in a registered direct offering, an aggregate of (i) 12,539,197 shares of the Company’s. The average price target represents a 143. com, its partners, representatives and employees assume no responsibility or liability for any use or mis-use of the product. Aytu Women's Health markets Fiera, a personal care device for women that is scientifically proven to enhance physical arousal and sexual desire. KenPharm, Aytu and Histogenics battered after discounted share offerings. In addition, in the event the warrants are exercised in full, Aytu expects to receive approximately $20 million in additional gross proceeds. For the biopharma industry investment, business development and competitive intelligence professionals who require information to support financing, partnering and licensing activities, BCIQ provides accurate information and context to support profitable and strategic decision making. AYTU - key executives, insider trading, ownership, revenue and average growth rates. The only place for free North American stock rankings incorporating insider commitment. Crazy moves in AYTU today. 0 million, before deducting the placement agent’s fees and other estimated offering expenses payable by Aytu. Aytu BioScience Announces Pricing of $7. Following the closing of this offering, the Company's pro forma cash balance as of September 30, 2019 would have been approximately $17. com), a national securities litigation firm, is investigating Aytu BioScience, Inc. aytu bioscience inc (aytu): * aytu bioscience (aytu) - received confirmation from u. All amounts are estimates except the Securities and Exchange Commission (the "SEC") registration fee. Analyst recommendations provided by FactSet shows that the consensus forecast for Aytu BioScience Inc. This was a very big move. Aytu Bioscience shares last traded at $1. 2 pct from its closing price on Thursday ** Company also offers Class B units consisting of 3,216 shares of its Series B convertible preferred stock ** As of March 1, company had 4. 455 likes · 75 talking about this · 1 was here. Unlike other intelligence solutions, BCIQ exclusively supports the unique needs of the biopharma industry and. The gross proceeds to Aytu from this offering are expected to be approximately $9. This makes me conclude Aytu made $700,000 profit on the 100,000 tests sold already and future profit of $3.